GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+64.56%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$403M
AUM Growth
+$403M
(+36%)
Cap. Flow
+$7.45M
Cap. Flow
% of AUM
1.85%
Top 10 Holdings %
Top 10 Hldgs %
52.59%
Holding
59
New
12
Increased
9
Reduced
13
Closed
17
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$20.6M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$18.6M |
| 3 |
Travere Therapeutics
TVTX
|
$12.9M |
| 4 |
Cogent Biosciences
COGT
|
$12.4M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$8.51M |
Top Sells
| 1 |
Mersana Therapeutics
MRSN
|
$12M |
| 2 |
Adverum Biotechnologies
ADVM
|
$12M |
| 3 |
Immunovant
IMVT
|
$10.4M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
$8.1M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$7.82M |
Sector Composition
| 1 | Healthcare | 92.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Adverum Biotechnologies
ADVM
$64.6M
| – | – | -1,161,375 | Closed | -$12M |
|
52
Agios Pharmaceuticals
AGIO
$2.19B
| – | – | -175,000 | Closed | -$6.13M |
|
53
Akebia Therapeutics
AKBA
$833M
| – | – | -250,000 | Closed | -$628K |
|
54
Altimmune
ALT
$338M
| – | – | -200,000 | Closed | -$2.64M |
|
|
55
Aurinia Pharmaceuticals
AUPH
$1.58B
| – | – | -550,000 | Closed | -$8.1M |
|
|
AVDL
56
Avadel Pharmaceuticals
AVDL
$1.43B
| – | – | -825,000 | Closed | -$4.16M |
|
57
CalciMedica
CALC
$37.7M
| – | – | -75,000 | Closed | -$953K |
|
58
Moderna
MRNA
$9.37B
| – | – | -10,000 | Closed | -$708K |
|
59
NextCure
NXTC
$13.5M
| – | – | -400,000 | Closed | -$3.52M |
|